Singh Sharad, Singh Gaurav
Department of Radiation Oncology, Kalyan Singh Super Speciality Cancer Institute, Lucknow, Uttar Pradesh, India.
Department of Head and Neck (Oral and Maxillofacial Surgery), Kalyan Singh Super Speciality Cancer Institute, Lucknow, Uttar Pradesh, India.
Natl J Maxillofac Surg. 2024 Sep-Dec;15(3):397-402. doi: 10.4103/njms.njms_4_24. Epub 2024 Nov 16.
Squamous-cell carcinoma of the head and neck is predominantly a loco regional disease, and the primary treatment methods are surgery and radiotherapy. For patients with locally-regionally advanced oropharyngeal cancer, concurrent chemoradiotherapy is the standard treatment.
The aim and objectives of study were a) to compare locoregional response in two arms, b) to compare acute and chronic treatment-related toxicities in the two arms, and c) to compare the quality of life. The study was conducted between August 2014 and April 2016, with 86 patients of histologically proven squamous-cell carcinoma of oropharynx. This is a prospective trial to assess the suitability of five versus six weekly radiotherapy fractions, along with concurrent cisplatin, given to the same total dose, in all stages of oropharyngeal cancer patients.
Patients were randomized into two arms: conventional arm (Arm A), which received 5 fractions per week RT -70GY/7 weeks/35#, and accelerated arm (Arm B), which received 6 fractions per week RT -70GY/6 weeks/35. Locoregional squamous-cell carcinoma improved significantly in the accelerated fractionation group compared with that in the conventional RT group.
Accelerated RT enhances improvement of locoregional control in the squamous-cell carcinoma of head and neck region, with reduction in overall treatment time and concurrent chemotherapy. Locoregional control of carcinoma improved significantly in the accelerated fractionation group compared with that in the conventional RT group.
头颈部鳞状细胞癌主要是一种局部区域性疾病,主要治疗方法是手术和放疗。对于局部区域晚期口咽癌患者,同步放化疗是标准治疗方法。
本研究的目的是:a)比较两组的局部区域反应;b)比较两组的急性和慢性治疗相关毒性;c)比较生活质量。该研究于2014年8月至2016年4月进行,纳入86例经组织学证实的口咽鳞状细胞癌患者。这是一项前瞻性试验,旨在评估在口咽癌患者的所有分期中,给予相同总剂量的情况下,每周5次与每周6次放疗分割联合顺铂同步治疗的适用性。
患者被随机分为两组:传统组(A组),接受每周5次放疗-70GY/7周/35次;加速组(B组),接受每周6次放疗-70GY/6周/35次。与传统放疗组相比,加速分割组的局部区域鳞状细胞癌有显著改善。
加速放疗可提高头颈部鳞状细胞癌的局部区域控制效果,同时缩短总治疗时间并联合化疗。与传统放疗组相比,加速分割组的癌灶局部区域控制有显著改善。